Category
Oral (LUO Remote) - Applied
Description
Diabetes mellitus remains the seventh leading cause of death within the country. This diagnosis can and often does lead to severe complications, creating implications for not only the patient but also families, caregivers, and the community. Most diabetic patients possess a diagnosis of type 2 diabetes mellitus. The healthcare industry continues to implement improvement with diabetic management and complications resulting from diabetes. Research suggests that the standard of care for patients with diabetes begins with lifestyle modification to improve glycemic control. New medications, such as Ozempic (semaglutide), have also been influential in diabetic management. Therefore, this scholarly project intended to study the two methods of medication management with GLP1-RA Ozempic and diabetic education with the hopes of improved glycemic control, improved weight, and improved comprehension of lifestyle management of the diagnosis. Patients with T2DM were tracked for a period of 12 weeks, assessing pre- and post intervention data. The data collected included A1C, weight in pounds, body mass index (BMI), and self care knowledge via a validated questionnaire. Participants were on the medication Ozempic (semaglutide) and received 12 weeks of education. Each participant received education via weekly emails. This scholarly project provided statistically significant evidence that med and the education are useful tools to manage T2DM. The significant results 0.0310 for weight, 0.05 for HbA1C and 0.0001 for Self Care Inventory-Revised. These results support the pairing of GLP1_RA Ozempic with diabetic education is useful for managing T2DM.
Diabetic Management with GLP1-RA Ozempic and Diabetic Education
Oral (LUO Remote) - Applied
Diabetes mellitus remains the seventh leading cause of death within the country. This diagnosis can and often does lead to severe complications, creating implications for not only the patient but also families, caregivers, and the community. Most diabetic patients possess a diagnosis of type 2 diabetes mellitus. The healthcare industry continues to implement improvement with diabetic management and complications resulting from diabetes. Research suggests that the standard of care for patients with diabetes begins with lifestyle modification to improve glycemic control. New medications, such as Ozempic (semaglutide), have also been influential in diabetic management. Therefore, this scholarly project intended to study the two methods of medication management with GLP1-RA Ozempic and diabetic education with the hopes of improved glycemic control, improved weight, and improved comprehension of lifestyle management of the diagnosis. Patients with T2DM were tracked for a period of 12 weeks, assessing pre- and post intervention data. The data collected included A1C, weight in pounds, body mass index (BMI), and self care knowledge via a validated questionnaire. Participants were on the medication Ozempic (semaglutide) and received 12 weeks of education. Each participant received education via weekly emails. This scholarly project provided statistically significant evidence that med and the education are useful tools to manage T2DM. The significant results 0.0310 for weight, 0.05 for HbA1C and 0.0001 for Self Care Inventory-Revised. These results support the pairing of GLP1_RA Ozempic with diabetic education is useful for managing T2DM.
Comments
Doctorate